Sensei Biotherapeutics, Inc.

NasdaqGM:SNSE Rapport sur les actions

Capitalisation boursière : US$12.3m

Sensei Biotherapeutics Croissance future

Future contrôle des critères 0/6

Sensei Biotherapeutics's earnings are forecast to decline at 18.9% per annum. EPS is expected to decline by 1.9% per annum.

Informations clés

-18.9%

Taux de croissance des bénéfices

-1.9%

Taux de croissance du BPA

Biotechs croissance des bénéfices27.1%
Taux de croissance des recettesn/a
Rendement futur des capitaux propres-59.8%
Couverture par les analystes

Low

Dernière mise à jour03 Oct 2024

Mises à jour récentes de la croissance future

Recent updates

Is Sensei Biotherapeutics (NASDAQ:SNSE) In A Good Position To Deliver On Growth Plans?

Nov 03
Is Sensei Biotherapeutics (NASDAQ:SNSE) In A Good Position To Deliver On Growth Plans?

We Think Sensei Biotherapeutics (NASDAQ:SNSE) Needs To Drive Business Growth Carefully

Jul 02
We Think Sensei Biotherapeutics (NASDAQ:SNSE) Needs To Drive Business Growth Carefully

Here's Why We're Watching Sensei Biotherapeutics' (NASDAQ:SNSE) Cash Burn Situation

Mar 14
Here's Why We're Watching Sensei Biotherapeutics' (NASDAQ:SNSE) Cash Burn Situation

We're Hopeful That Sensei Biotherapeutics (NASDAQ:SNSE) Will Use Its Cash Wisely

Aug 14
We're Hopeful That Sensei Biotherapeutics (NASDAQ:SNSE) Will Use Its Cash Wisely

Sensei Biotherapeutics GAAP EPS of -$0.34 beats by $0.06

Aug 09

Here's Why We're Watching Sensei Biotherapeutics' (NASDAQ:SNSE) Cash Burn Situation

Apr 18
Here's Why We're Watching Sensei Biotherapeutics' (NASDAQ:SNSE) Cash Burn Situation

Sensei Biotherapeutics (NASDAQ:SNSE) Is In A Good Position To Deliver On Growth Plans

Nov 16
Sensei Biotherapeutics (NASDAQ:SNSE) Is In A Good Position To Deliver On Growth Plans

Prévisions de croissance des bénéfices et des revenus

NasdaqGM:SNSE - Estimations futures des analystes et données financières antérieures (USD Millions )
DateRecettesLes revenusFlux de trésorerie disponibleCash from OpMoy. Nombre d'analystes
12/31/2026N/A-44N/A-492
12/31/2025N/A-37N/A-402
12/31/2024N/A-31N/A-323
6/30/2024N/A-30-24-24N/A
3/31/2024N/A-32-28-28N/A
12/31/2023N/A-34-32-32N/A
9/30/2023N/A-39-36-35N/A
6/30/2023N/A-45-38-38N/A
3/31/2023N/A-46-40-40N/A
12/31/2022N/A-49-39-39N/A
9/30/2022N/A-46-38-37N/A
6/30/2022N/A-42-37-36N/A
3/31/2022N/A-41-32-30N/A
12/31/2021N/A-37-32-30N/A
9/30/2021N/A-33-27-25N/A
6/30/2021N/A-28-28-25N/A
3/31/2021N/A-23-24-22N/A
12/31/2020N/A-20-19-18N/A
9/30/2020N/A-23-18-17N/A
12/31/2019N/A-21-9-9N/A

Prévisions de croissance des analystes

Taux de revenus par rapport au taux d'épargne: SNSE is forecast to remain unprofitable over the next 3 years.

Bénéfices vs marché: SNSE is forecast to remain unprofitable over the next 3 years.

Croissance élevée des bénéfices: SNSE is forecast to remain unprofitable over the next 3 years.

Chiffre d'affaires vs marché: Insufficient data to determine if SNSE's revenue is forecast to grow faster than the US market.

Croissance élevée des revenus: SNSE is forecast to have no revenue next year.


Prévisions de croissance du bénéfice par action


Rendement futur des capitaux propres

ROE futur: SNSE is forecast to be unprofitable in 3 years.


Découvrir les entreprises en croissance